Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04343885
Title In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia
Indications

prostate cancer

prostate adenocarcinoma

Therapies

Docetaxel

Docetaxel + lutetium Lu 177 vipivotide tetraxetan

Age Groups: adult | senior
Covered Countries


No variant requirements are available.